CARsgen Therapeutics Holdings Limited (HK:2171), a China-based company involved in developing innovative CAR T-cell therapies, announced on Wednesday that the updated long-term follow-up results for the Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel, R&D code: CT053, an autologous CAR T-cell product targeting BCMA) have been presented as a poster at the 22nd International Myeloma Society (IMS) Annual Meeting.

The poster was titled 'Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma' (Abstract number: PA-029).

In this study, a total of 14 patients with relapsed or refractory multiple myeloma (R/R MM) received a single infusion of zevor-cel. As of 22 February 2025, the median follow-up duration was 53.3 months (range: 14.8, 63.5).

The overall response rate was 100%, with 11 (78.6%) patients achieving complete response (CR) or stringent complete response (sCR). All patients who achieved CR or better were minimal residual disease (MRD) negative at 10-5 threshold. One patient remained in sCR at 59.3 months in the study. The median progression-free survival (mPFS) and the median duration of response (mDoR) were 44.1 months and 43.2 months in CR/sCR patients, respectively. The median overall survival (OS) was not reached. The proportion of patients surviving at 24, 36, 48 and 60 months after infusion were 100%, 92.3%, 84.6% and 76.9%, respectively.

At approximately 5 years of follow-up, zevor-cel demonstrated a manageable safety profile while eliciting deep and durable responses in R/R MM patients, CARsgen said.

Regarding safety, there were no reports of Grade 3 or higher cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), delayed neurotoxicities, second primary malignancy or other delayed adverse events.